Sign in

Private company

Apexigen, Inc.

Apexigen, Inc. is an American pharmaceutical preparations company based in San Carlos.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Carlos, California1
  • Incorporated inDE2
  • Business address900 Industrial Road, Suite C, San Carlos, Ca 940702
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3-$32.7M in 2022+13% since 2021
-$40.0M-$30.0M-$20.0M-$10.0M02021: -$29.0M-$29.0M20212022: -$32.7M-$32.7M2022+13%
Net income3-$32.1M in 2022+11% since 2021
-$40.0M-$30.0M-$20.0M-$10.0M02021: -$28.9M-$28.9M20212022: -$32.1M-$32.1M2022+11%
Fiscal year2020202120222023
Research and development$21.7M3$23.0M3
Operating expenses$29.0M3$32.7M3
Operating income-$29.0M3-$32.7M3
Income tax$03$03
Net income-$28.9M3-$32.1M3
Earnings per share-$1.603-$1.623
Earnings per share (diluted)-$1.603-$1.623
Shares (weighted, basic)18.0M shares319.8M shares3
Shares (weighted, diluted)18.0M shares319.8M shares3

Compare Apexigen, Inc. with another company

Corporate structure

Apexigen, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Apexigen, Inc.

  • Apexigen, Inc. San Carlos, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Apexigen, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$974.0K3 Dec 31, 2022$1.0M3 Dec 31, 2021−3.4%
Accumulated depreciation$824.0K3 Dec 31, 2022$763.0K3 Dec 31, 2021+8.0%
Property and equipment, net$150.0K3 Dec 31, 2022$245.0K3 Dec 31, 2021−38.8%
Operating-lease assets (leased space)$100.0K3 Dec 31, 2022$483.0K3 Dec 31, 2021−79.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$14.8M3 Dec 31, 2022$23.4M3 Dec 31, 2021−36.9%
Marketable securities, current$2.0M3 Dec 31, 2022$12.9M3 Dec 31, 2021−84.5%
Debt securities available for sale$2.0M3 Dec 31, 2022$12.9M3 Dec 31, 2021−84.5%

Leadership

Who has led Apexigen, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Samuel P. Wertheimer2021
  2. Xiaodong Yang2022–2023

President

  1. Scott A. Katzmann2021
  2. Francis Willard Sarena2023

Chief financial officer

  1. Patrick A. Sturgeon2021
  2. William E. Duke2022–2023

Chief operating officer

  1. Francis Willard Sarena2022–2023
2025
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorDan Zabrowski named Feb 14, 202325
  • Chair of the BoardMeenu Karson named Feb 14, 202325

Former names

  • Brookline Capital Acquisition Corp.Jul 17, 2020 to Aug 1, 20222

Timeline

  1. Aug 23, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights26
  2. Aug 22, 20238-K Shareholder vote27
  3. Aug 18, 20238-K Listing notice or transfer28
  4. Aug 15, 20238-K Other events29
  5. May 24, 20238-K Entered a material agreement; Regulation FD disclosure30
  6. Apr 12, 20238-K Listing notice or transfer31
  7. Feb 27, 20238-K Exit or restructuring costs; Executive or director change; Other events32
  8. Feb 14, 20238-K Executive or director change33
  9. Feb 1, 20238-K Unregistered sale of shares34
  10. Jan 25, 20238-K Entered a material agreement; Unregistered sale of shares; Other events35
  11. Nov 14, 20228-K Change of auditor; Other events36
  12. Aug 18, 20228-K Financial statements and exhibits37
  13. Aug 8, 2022New chief executive Xiaodong Yang becomes CEO7
  14. Jan 28, 2021New chief executive Samuel P. Wertheimer becomes CEO8

Filings

163 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 26 major events, 51 insider forms, 9 large holders, 1 private raises, 68 other. The latest 20:

  1. Sep 5, 202315-12G EDGAR
  2. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  3. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  4. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  5. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  6. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  7. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  8. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  9. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  10. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  11. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  12. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  13. Aug 25, 20234 FORM 4 SUBMISSION EDGAR
  14. Aug 24, 20233/A FORM 3/A SUBMISSION EDGAR
  15. Aug 23, 2023S-8 POS EDGAR
  16. Aug 23, 20238-K EDGAR
  17. Aug 22, 20238-K EDGAR
  18. Aug 18, 20238-K EDGAR
  19. Aug 16, 2023DEFA14A EDGAR
  20. Aug 15, 20238-K EDGAR

The 163 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$5.6M 2023–2023
Money received by yearMoney received by year, 2023–2023: $5.6M in all. Private raises (Form D) $5.6M.$0$2M$4M$6M2023 · Private raises (Form D): $5.6M2023
Figures by year
YearPrivate raises (Form D)Total
2023$5.6M$5.6M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jan 30, 2023Raised $5.6 million in a private offering of equity25 Form D: 13 investors so far Form D

SEC filer profile

How Apexigen, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARApexigen, Inc.1
  • CIK0001814140
  • Employer ID (EIN)85-12602441
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address900 Industrial Road, Suite C, San Carlos, CA 940701
  • Phone650.931.62361
  • Shares outstanding24,861,926 as of Aug 4, 20235
  • Public float$203.6M as of Jun 30, 20223
  • On EDGAR sinceJul 17, 20201
  • Filings202 in all: 4 (40), 8-K (28), 425 (21), 3 (20), CORRESP (10), 10-Q (8), 424B3 (8), EFFECT (7)1
    All 36 form types

    SC 13G (7), S-1/A (6), UPLOAD (6), NT 10-Q (4), S-1 (4), S-4/A (4), SC 13G/A (4), 10-K (2), 25-NSE (2), 8-K/A (2), POS AM (2), 15-12G (1), 3/A (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), CERT (1), D (1), DEF 14A (1), DEFA14A (1), DEFM14A (1), DRS (1), NT 10-K (1), PRE 14A (1), S-4 (1), S-8 (1), S-8 POS (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Feb 22, 2023
    Quarterly report (10-Q) Aug 10, 2023
    Proxy statement (DEF 14A) Mar 28, 2022
    Latest 8-K (8-K) Aug 23, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43